Dedicated MASLD/MASH trials for both compounds will clarify whether retatrutide's glucagon-mediated hepatic fat clearance translates into superior histological outcomes
Lack of medication adherence may limit the long-term health benefits, such as cardiovascular risk reduction, associated with GLP-1 RA therapy, the study authors wrote
The Department of Health and Human Services asked the Department of Justice to investigate the company for potential violations of the Food, Drug, and Cosmetic Act (FDCA)
For now, the data speak clearly
In the head-to-head dosage comparison , tirzepatide generally produces greater weight loss (15-22% vs 12-15% with semaglutide over 72 weeks)
There is currently no confirmed evidence that retatrutide causes cancer in humans